Philippe Calais
CEO & Executive Chairman of the Board

Good morning, everyone, and thank you very much for joining us for this first ever webcast to cover our company research and corporate strategy. I'm Philippe Calais, the Chief Executive Officer and Chairman of the Board of Directors. Having an extensive experience in pharma and biotech, I joined as the first independent Board member right after the company inception in 2018, then became the Chairman of the Board in 2021 as we completed our first public offering and more recently, became the Chief Executive Officer last October.

It has been quite a ride since 2018, and we hope that this webcast will give you a better idea of what we have achieved so far of our strategy and our plans going forward.

First of all, our usual disclaimer. And then who really are we? Our company was founded by two Harvard faculty members, Professor Anna Moore and Dr. Zdravka Medarova from the Massachusetts General Hospital and the Harvard Medical School. Their goal was to identify and develop new therapeutics to target advanced tumors.

Since our first public offering in 2021, approximately $100 million were invested through financing, but also through government-funded non-dilutive grants. We aim at redefining the boundaries of advanced cancer care by pioneering different but complementary approaches that we describe as our three shots on goal strategy.

First of